TXMD Stock Overview
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
TherapeuticsMD, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.88 |
| 52 Week High | US$4.73 |
| 52 Week Low | US$1.86 |
| Beta | 1.04 |
| 1 Month Change | -17.90% |
| 3 Month Change | -17.90% |
| 1 Year Change | -47.92% |
| 3 Year Change | -96.76% |
| 5 Year Change | -99.13% |
| Change since IPO | -96.24% |
Recent News & Updates
Recent updates
TherapeuticsMD raises $7M in private placement
Oct 03TherapeuticsMD appoints interim co-CEOs
Sep 12Therapeutics MD Q2 Earnings Preview
Aug 12TherapeuticsMD receives $15M equity investment from Rubric Capital
Aug 01TherapeuticsMD jumps 12% as top investor discloses insider purchase
Jul 19TherapeuticsMD plunges 42% as merger agreement ends
Jul 13TherapeuticsMD risks bankruptcy as EW Healthcare extends tender offer for acquisition
Jul 06TherapeuticsMD: Privatization Deal Expected To Meet With Shareholder Pushback
Jun 16TherapeuticsMD: Looking For A Potential Turnaround After Divesting VitaCare Business
Mar 14TherapeuticsMD: Time For Bulls To Take A Contrarian Approach
Oct 22TherapeuticsMD: The Long Road To Profitability
Jul 08TherapeuticsMD drops 3% despite consensus beating Q1 results
May 06TherapeuticsMD, Inc. (NASDAQ:TXMD): Are Analysts Optimistic?
Feb 24
TherapeuticsMD: Annovera May Save The Day
Feb 04TherapeuticsMD, Inc. (NASDAQ:TXMD) Analysts Are More Bearish Than They Used To Be
Jan 29What Type Of Shareholders Make Up TherapeuticsMD, Inc.'s (NASDAQ:TXMD) Share Registry?
Jan 27Have Insiders Been Buying TherapeuticsMD, Inc. (NASDAQ:TXMD) Shares?
Dec 30
TherapeuticsMD (NASDAQ:TXMD) Share Prices Have Dropped 87% In The Last Five Years
Dec 09TherapeuticsMD: Q3 Report Reveals Strong Rebound And Bolsters Commercial Outlook
Nov 25Therapeutics MD EPS beats by $0.01, beats on revenue
Nov 09Shareholder Returns
| TXMD | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -1.1% | -1.5% | -3.2% |
| 1Y | -47.9% | 9.7% | 19.3% |
Return vs Industry: TXMD underperformed the US Pharmaceuticals industry which returned 9.7% over the past year.
Return vs Market: TXMD underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| TXMD volatility | |
|---|---|
| TXMD Average Weekly Movement | 5.5% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TXMD's share price has been volatile over the past 3 months.
Volatility Over Time: TXMD's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 1 | Marlan Walker | www.therapeuticsmd.com |
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.
TherapeuticsMD, Inc. Fundamentals Summary
| TXMD fundamental statistics | |
|---|---|
| Market cap | US$21.68m |
| Earnings (TTM) | -US$7.70m |
| Revenue (TTM) | US$1.30m |
16.7x
P/S Ratio-2.8x
P/E RatioIs TXMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TXMD income statement (TTM) | |
|---|---|
| Revenue | US$1.30m |
| Cost of Revenue | US$0 |
| Gross Profit | US$1.30m |
| Other Expenses | US$9.00m |
| Earnings | -US$7.70m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.67 |
| Gross Margin | 100.00% |
| Net Profit Margin | -591.32% |
| Debt/Equity Ratio | 0% |
How did TXMD perform over the long term?
See historical performance and comparison